7.1M XNYS Volume
XNYS 20 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Prem S. Shah | EVP and Group President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 846 | 0 | - | - | Stock Option | |
| Prem S. Shah | EVP and Group President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.21 per share. | 17 Mar 2025 | 846 | 43,189 (0%) | 0% | 62.2 | 52,630 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 7,513 | 0 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Sale of securities on an exchange or to another person at price $ 66.35 per share. | 05 Mar 2025 | 7,513 | 8,394 (0%) | 0% | 66.4 | 498,488 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.21 per share. | 05 Mar 2025 | 7,513 | 15,907 (0%) | 0% | 62.2 | 467,384 | Common Stock |
| J. David Joyner | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.72 per share. | 28 Feb 2025 | 1,944 | 46,717 (0%) | 0% | 65.7 | 127,760 | Common Stock |
| Samrat S. Khichi | EVP, CPO and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.72 per share. | 28 Feb 2025 | 5,604 | 20,106 (0%) | 0% | 65.7 | 368,295 | Common Stock |
| Thomas F. Cowhey | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.72 per share. | 28 Feb 2025 | 5,318 | 45,256 (0%) | 0% | 65.7 | 349,499 | Common Stock |
| Michael F. Mahoney | Director | Purchase of securities on an exchange or from another person at price $ 66.70 per share. | 18 Feb 2025 | 30,000 | 39,356 (0%) | 0% | 66.7 | 2,001,000 | Common Stock (By Trust) |
| Anne M. Finucane | Director | Gift of securities by or to the insider at price $ 56.86 per share. | 05 Dec 2024 | 2,665 | 4,567 (0%) | 0% | 56.9 | 151,532 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 59.85 per share. | 30 Nov 2024 | 50,125 | 50,125 | - | 59.8 | 2,999,981 | Common Stock (Restricted) |
| Steven H. Nelson | EVP and President, Aetna | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2024 | 124,378 | 124,378 | - | - | Premium Stock Option | |
| J. David Joyner | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2024 | 1,492,537 | 1,492,537 | - | - | Premium Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.85 per share. | 30 Nov 2024 | 86 | 8,394 (0%) | 0% | 59.8 | 5,147 | Common Stock |
| Tilak Mandadi | EVP, Chief DDAT Officer | Grant, award, or other acquisition of securities at price $ 59.85 per share. | 30 Nov 2024 | 50,125 | 99,747 | - | 59.8 | 2,999,981 | Common Stock (RSU) |
| Prem S. Shah | EVP and Group President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2024 | 746,268 | 746,268 | - | - | Premium Stock Option | |
| Joyner J. David | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2024 | 1,000,000 | 1,000,000 | - | - | Premium Stock Option | |
| Joyner J. David | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2024 | 492,537 | 492,537 | - | - | Premium Stock Appreciation Right | |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,364 | 36,887 (0%) | 0% | 57.1 | 134,984 | Common Stock |
| Guy P. Sansone | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,200 | 8,360 (0%) | 0% | 57.1 | 125,620 | Common Stock |
| J. Scott Kirby | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,933 | 8,566 (0%) | 0% | 57.1 | 167,474 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,200 | 4,514 (0%) | 0% | 57.1 | 125,620 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 2,933 | 24,436 | - | - | Deferred Stock Units | |
| Nancy-Ann Deparle | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,331 | 34,169 (0%) | 0% | 57.1 | 133,100 | Common Stock |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,331 | 123,765 (0%) | 0% | 57.1 | 133,100 | Common Stock |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 2,200 | 12,173 | - | - | Deferred Stock Units | |
| Leslie V. Norwalk | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,200 | 2,200 (0%) | 0% | 57.1 | 125,620 | Common Stock |
| Michael F. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,200 | 6,201 (0%) | 0% | 57.1 | 125,620 | Common Stock |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 2,200 | 34,934 | - | - | Deferred Stock Units | |
| Douglas H. Shulman | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,200 | 2,200 (0%) | 0% | 57.1 | 125,620 | Common Stock |
| Jeffrey R. Balser | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,375 | 9,652 (0%) | 0% | 57.1 | 135,613 | Common Stock |
| Larry Robbins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 2,933 | 2,933 | - | - | Deferred Stock Units | |
| Tilak Mandadi | EVP, Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.24 per share. | 31 Aug 2024 | 13,097 | 40,414 (0%) | 0% | 57.2 | 749,672 | Common Stock |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 57.52 per share. | 16 May 2024 | 2,347 | 34,523 (0%) | 0% | 57.5 | 134,999 | Common Stock |
| J. Scott Kirby | Director | Grant, award, or other acquisition of securities at price $ 57.52 per share. | 16 May 2024 | 2,912 | 5,633 (0%) | 0% | 57.5 | 167,498 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 57.52 per share. | 16 May 2024 | 2,314 | 2,314 (0%) | 0% | 57.5 | 133,101 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,912 | 21,017 | - | - | Share Credits | |
| Nancy-Ann Deparle | Director | Grant, award, or other acquisition of securities at price $ 57.52 per share. | 16 May 2024 | 2,314 | 31,838 (0%) | 0% | 57.5 | 133,101 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,302 | 35,561 | - | - | Share Credits | |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 57.52 per share. | 16 May 2024 | 2,314 | 121,434 (0%) | 0% | 57.5 | 133,101 | Common Stock |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,184 | 9,747 | - | - | Share Credits | |
| Michael F. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 57.52 per share. | 16 May 2024 | 2,184 | 4,001 (0%) | 0% | 57.5 | 125,624 | Common Stock |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,184 | 31,994 | - | - | Share Credits | |
| Jeffrey R. Balser | Director | Grant, award, or other acquisition of securities at price $ 57.52 per share. | 16 May 2024 | 2,184 | 7,277 (0%) | 0% | 57.5 | 125,624 | Common Stock |
| Edward J. Ludwig | Director | Purchase of securities on an exchange or from another person at price $ 53.88 per share. | 02 May 2024 | 1,000 | 21,630 (0%) | 0% | 53.9 | 53,879 | Common Stock |
| Michael F. Mahoney | Director | Purchase of securities on an exchange or from another person at price $ 54.49 per share. | 02 May 2024 | 9,181 | 9,356 (0%) | 0% | 54.5 | 500,294 | Common Stock (By Trust) |
| Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 79.56 per share. | 01 Apr 2024 | 45,248 | 45,248 | - | 79.6 | 3,599,931 | Common Stock (Restricted) |
| Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 188,087 | 188,087 | - | - | Stock Option | |
| Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.56 per share. | 01 Apr 2024 | 61,953 | 74,687 (0%) | 0% | 79.6 | 4,928,981 | Common Stock |
| J. David Joyner | EVP&President-PharmacyServices | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 28,280 | 44,241 | - | 0 | Common Stock (Restricted) | |
| Brian A. Kane | EVP/President, Aetna | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 12,569 | 12,569 | - | 0 | Common Stock (Restricted) | |
| Brian A. Kane | EVP/President, Aetna | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 52,246 | 52,246 | - | - | Stock Option | |
| Samrat S. Khichi | EVP, CPO and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 12,569 | 44,490 | - | 0 | Common Stock (Restricted) | |
| Samrat S. Khichi | EVP, CPO and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 52,246 | 52,246 | - | - | Stock Option | |
| Thomas F. Cowhey | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 62,695 | 62,695 | - | - | Stock Option | |
| Thomas F. Cowhey | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 15,082 | 47,995 | - | 0 | Common Stock (Restricted) | |
| Thomas F. Cowhey | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.56 per share. | 01 Apr 2024 | 1,719 | 35,642 (0%) | 0% | 79.6 | 136,764 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.56 per share. | 01 Apr 2024 | 1,892 | 9,592 (0%) | 0% | 79.6 | 150,528 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 79.56 per share. | 01 Apr 2024 | 10,683 | 15,109 | - | 79.6 | 849,939 | Common Stock (Restricted) |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.56 per share. | 01 Apr 2024 | 1,112 | 8,480 (0%) | 0% | 79.6 | 88,471 | Common Stock |
| Laurie P. Havanec | EVP and Chief People Officer | 01 Apr 2024 | 9,426 | 9,426 | - | 79.6 | 749,933 | Common Stock (Restricted) | |
| Laurie P. Havanec | EVP and Chief People Officer | 01 Apr 2024 | 7,630 | 37,553 (0%) | 0% | 79.6 | 607,043 | Common Stock | |
| Laurie P. Havanec | EVP and Chief People Officer | 01 Apr 2024 | 39,184 | 39,184 | - | - | Stock Option | ||
| Tilak Mandadi | EVP, Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 67,920 | 67,920 | - | - | Stock Option | |
| Tilak Mandadi | EVP, Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 16,339 | 82,904 | - | 0 | Common Stock (RSU) | |
| Prem S. Shah | EVP and Pres-Pharm, Consumer W | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 15,082 | 37,057 | - | 0 | Common Stock (Restricted) | |
| Prem S. Shah | EVP and Pres-Pharm, Consumer W | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.56 per share. | 01 Apr 2024 | 2,653 | 47,273 (0%) | 0% | 79.6 | 211,073 | Common Stock |
| Prem S. Shah | EVP and Pres-Pharm, Consumer W | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 62,695 | 62,695 | - | - | Stock Option | |
| Prem S. Shah | EVP and Pres-Pharm, Consumer W | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.56 per share. | 01 Apr 2024 | 5,239 | 42,034 (0%) | 0% | 79.6 | 416,815 | Common Stock |
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | 01 Apr 2024 | 825 | 11,211 (0%) | 0% | 79.6 | 65,637 | Common Stock | |
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | 01 Apr 2024 | 28,735 | 28,735 | - | - | Stock Option | ||
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | 01 Apr 2024 | 6,913 | 23,666 | - | 79.6 | 549,998 | Common Stock (Restricted) | |
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | 01 Apr 2024 | 1,473 | 12,036 (0%) | 0% | 79.6 | 117,192 | Common Stock | |
| J. David Joyner | EVP&President-PharmacyServices | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.19 per share. | 28 Feb 2024 | 1,970 | 40,681 (0%) | 0% | 75.2 | 148,124 | Common Stock |
| Samrat S. Khichi | EVP, CPO and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.19 per share. | 28 Feb 2024 | 6,210 | 9,750 (0%) | 0% | 75.2 | 466,930 | Common Stock |
| Thomas F. Cowhey | SVP, Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.19 per share. | 28 Feb 2024 | 5,641 | 28,631 (0%) | 0% | 75.2 | 424,147 | Common Stock |
| S. Prem Shah | EVP and Pres-Pharm, Consumer W | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.43 per share. | 26 Feb 2024 | 261 | 43,185 (0%) | 0% | 76.4 | 19,948 | Common Stock |
| K Chaguturu Sreekanth | EVP and Chief Medical Officer | 26 Feb 2024 | 355 | 9,333 (0%) | 0% | 76.4 | 27,133 | Common Stock | |
| Havanec Laurie P. | EVP and Chief People Officer | 26 Feb 2024 | 6,698 | 45,183 (0%) | 0% | 76.4 | 511,928 | Common Stock | |
| Shah S. Prem | EVP and Pres-Pharm, Consumer W | Sale of securities on an exchange or to another person at price $ 76.95 per share. | 16 Feb 2024 | 29,473 | 39,764 (0%) | 0% | 76.9 | 2,267,947 | Common Stock |
| Laurie P. Havanec | EVP and Chief People Officer | 12 Feb 2024 | 16,817 | 37,203 (0%) | 0% | 0 | Common Stock | ||
| S. Shah Prem | EVP and Pres-Pharm, Consumer W | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 13,313 | 69,237 (0%) | 0% | 0 | Common Stock | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 2,452 | 7,150 (0%) | 0% | 0 | Common Stock | |
| K Chaguturu Sreekanth | EVP and Chief Medical Officer | 12 Feb 2024 | 1,926 | 8,645 (0%) | 0% | 0 | Common Stock | ||
| Clark D. James | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.48 per share. | 14 Dec 2023 | 122 | 8,760 | - | 68.5 | 8,355 | Common Stock (Restricted) |
| M. Finucane Anne | Director | Gift of securities by or to the insider at price $ 74.28 per share. | 07 Dec 2023 | 3,450 | 7,232 (0%) | 0% | 74.3 | 256,266 | Common Stock |
| F. Thomas Cowhey | SVP, Interim CFO | Grant, award, or other acquisition of securities at price $ 67.95 per share. | 30 Nov 2023 | 7,358 | 60,938 | - | 67.9 | 499,976 | Common Stock (Restricted) |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2023 | 2,422 | 14,522 | - | - | Share Credits | |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 69.13 per share. | 15 Nov 2023 | 1,998 | 32,176 (0%) | 0% | 69.1 | 138,122 | Common Stock |
| J. Scott Kirby | Director | Grant, award, or other acquisition of securities at price $ 69.13 per share. | 15 Nov 2023 | 2,422 | 2,721 (0%) | 0% | 69.1 | 167,433 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 69.13 per share. | 15 Nov 2023 | 1,925 | 3,362 (0%) | 0% | 69.1 | 133,075 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2023 | 1,817 | 17,734 | - | - | Share Credits | |
| Nancy-Ann Deparle | Director | Grant, award, or other acquisition of securities at price $ 69.13 per share. | 15 Nov 2023 | 1,925 | 29,524 (0%) | 0% | 69.1 | 133,075 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2023 | 4,411 | 29,639 | - | - | Share Credits | |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2023 | 1,925 | 78,483 | - | - | Share Credits | |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 69.13 per share. | 15 Nov 2023 | 1,925 | 10,682 (0%) | 0% | 69.1 | 133,075 | Common Stock |
| Michael F. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 69.13 per share. | 15 Nov 2023 | 1,817 | 1,817 (0%) | 0% | 69.1 | 125,609 | Common Stock |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2023 | 1,817 | 29,199 | - | - | Share Credits | |
| Jeffrey R. Balser | Director | Grant, award, or other acquisition of securities at price $ 69.13 per share. | 15 Nov 2023 | 1,817 | 5,093 (0%) | 0% | 69.1 | 125,609 | Common Stock |
| Edward J. Ludwig | Director | Purchase of securities on an exchange or from another person at price $ 70.46 per share. | 03 Nov 2023 | 2,000 | 20,630 (0%) | 0% | 70.5 | 140,930 | Common Stock |
| J. Scott Kirby | Director | Grant, award, or other acquisition of securities at price $ 69.82 per share. | 02 Oct 2023 | 299 | 299 (0%) | 0% | 69.8 | 20,876 | Common Stock |
| Tilak Mandadi | EVP, Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.17 per share. | 31 Aug 2023 | 13,053 | 20,229 (0%) | 0% | 65.2 | 850,664 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.17 per share. | 31 Aug 2023 | 3,508 | 50,987 (0%) | 0% | 65.2 | 228,616 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Sale of securities on an exchange or to another person at price $ 74.80 per share. | 03 Aug 2023 | 2,631 | 27,826 (0%) | 0% | 74.8 | 196,792 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Sale of securities on an exchange or to another person at price $ 74.94 per share. | 03 Aug 2023 | 23,128 | 4,698 (0%) | 0% | 74.9 | 1,733,212 | Common Stock |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 2,068 | 11,816 | - | - | Share Credits | |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 69.31 per share. | 18 May 2023 | 1,329 | 30,178 (0%) | 0% | 69.3 | 92,113 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 69.31 per share. | 18 May 2023 | 1,437 | 1,437 (0%) | 0% | 69.3 | 99,598 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 1,329 | 15,534 | - | - | Share Credits | |
| Nancy-Ann Deparle | Director | Grant, award, or other acquisition of securities at price $ 69.31 per share. | 18 May 2023 | 1,437 | 27,599 (0%) | 0% | 69.3 | 99,598 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,917 | 24,634 | - | - | Share Credits | |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 1,437 | 74,674 | - | - | Share Credits | |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 69.31 per share. | 18 May 2023 | 1,437 | 8,757 (0%) | 0% | 69.3 | 99,598 | Common Stock |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 1,329 | 26,715 | - | - | Share Credits | |
| Jeffrey R. Balser | Director | Grant, award, or other acquisition of securities at price $ 69.31 per share. | 18 May 2023 | 1,329 | 3,276 (0%) | 0% | 69.3 | 92,113 | Common Stock |
| Karen S. Lynch | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 69.75 per share. | 03 May 2023 | 14,000 | 431,392 (0%) | 0% | 69.8 | 976,567 | Common Stock (By Trust) |
| Michelle A. Peluso | EVP and Co-President of Retail | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 89,073 | 89,073 | - | - | Stock Option | |
| Michelle A. Peluso | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.31 per share. | 01 Apr 2023 | 98,299 | 124,383 (0%) | 0% | 74.3 | 7,304,599 | Common Stock |
| Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.31 per share. | 01 Apr 2023 | 93,677 | 112,933 (0%) | 0% | 74.3 | 6,961,138 | Common Stock |
| Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 244,952 | 244,952 | - | - | Stock Option | |
| Shawn M. Guertin | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 148,456 | 148,456 | - | - | Stock Option | |
| J. David Joyner | EVP&President-PharmacyServices | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 51,959 | 51,959 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 74.31 per share. | 01 Apr 2023 | 2,186 | 9,080 | - | 74.3 | 162,442 | Common Stock (Restricted) |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 9,649 | 9,649 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.31 per share. | 01 Apr 2023 | 1,471 | 30,457 (0%) | 0% | 74.3 | 109,310 | Common Stock |
| Laurie P. Havanec | EVP and Chief People Officer | 01 Apr 2023 | 51,959 | 51,959 | - | - | Stock Option | ||
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.31 per share. | 01 Apr 2023 | 3,856 | 35,067 (0%) | 0% | 74.3 | 286,539 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 74,228 | 74,228 | - | - | Stock Option | |
| Tilak Mandadi | EVP, Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 96,496 | 96,496 | - | - | Stock Option | |
| Prem S. Shah | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.31 per share. | 01 Apr 2023 | 3,221 | 49,364 (0%) | 0% | 74.3 | 239,353 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 89,073 | 89,073 | - | - | Stock Option | |
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | 01 Apr 2023 | 40,825 | 40,825 | - | - | Stock Option | ||
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | 01 Apr 2023 | 1,854 | 6,427 (0%) | 0% | 74.3 | 137,771 | Common Stock | |
| J. David Joyner | EVP&President-PharmacyServices | Grant, award, or other acquisition of securities at price $ 83.54 per share. | 28 Feb 2023 | 23,940 | 23,940 | - | 83.5 | 1,999,948 | Common Stock (Restricted) |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.54 per share. | 28 Feb 2023 | 179 | 26,151 (0%) | 0% | 83.5 | 14,954 | Common Stock |
| Michelle A. Peluso | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.77 per share. | 27 Feb 2023 | 12,304 | 222,682 (0%) | 0% | 85.8 | 1,055,314 | Common Stock |
| Laurie P. Havanec | EVP and Chief People Officer | 27 Feb 2023 | 4,046 | 20,386 (0%) | 0% | 85.8 | 347,025 | Common Stock | |
| Prem S. Shah | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.77 per share. | 27 Feb 2023 | 226 | 44,403 (0%) | 0% | 85.8 | 19,384 | Common Stock |
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | 27 Feb 2023 | 120 | 4,105 (0%) | 0% | 83.5 | 10,025 | Common Stock | |
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | 27 Feb 2023 | 318 | 3,871 (0%) | 0% | 85.8 | 27,275 | Common Stock | |
| Michelle A. Peluso | EVP and Co-President of Retail | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 192,554 | 207,465 (0%) | 0% | 0 | Common Stock | |
| Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 206,610 | 206,610 (0%) | 0% | 0 | Common Stock | |
| Thomas M. Moriarty | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 93.19 per share. | 31 Dec 2022 | 292,856 | 315,273 (0%) | 0% | 93.2 | 27,291,251 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 98.24 per share. | 15 Dec 2022 | 36,490 | 608,129 (0%) | 0% | 98.2 | 3,584,869 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.21 per share. | 15 Dec 2022 | 36,490 | 644,619 (0%) | 0% | 62.2 | 2,270,043 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 78.05 per share. | 15 Dec 2022 | 100,976 | 709,105 (0%) | 0% | 78.1 | 7,881,177 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 98.40 per share. | 15 Dec 2022 | 100,976 | 608,129 (0%) | 0% | 98.4 | 9,936,311 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2022 | 36,490 | 0 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2022 | 100,976 | 24,248 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.65 per share. | 01 Dec 2022 | 153 | 26,177 (0%) | 0% | 101.6 | 15,552 | Common Stock |
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.88 per share. | 29 Nov 2022 | 442 | 2,896 (0%) | 0% | 100.9 | 44,589 | Common Stock |
| Anne M. Finucane | Director | Gift of securities by or to the insider at price $ 97.35 per share. | 18 Nov 2022 | 800 | 28,964 (0%) | 0% | 97.4 | 77,880 | Common Stock |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 94.93 per share. | 17 Nov 2022 | 131 | 18,630 (0%) | 0% | 94.9 | 12,436 | Common Stock |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2022 | 1,323 | 9,681 | - | - | Share Credits | |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 94.93 per share. | 17 Nov 2022 | 1,323 | 28,849 (0%) | 0% | 94.9 | 125,592 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 94.93 per share. | 17 Nov 2022 | 1,402 | 2,811 (0%) | 0% | 94.9 | 133,092 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2022 | 1,764 | 14,107 | - | - | Share Credits | |
| Nancy-Ann Deparle M. | Director | Grant, award, or other acquisition of securities at price $ 94.93 per share. | 17 Nov 2022 | 1,402 | 26,162 (0%) | 0% | 94.9 | 133,092 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2022 | 3,212 | 20,574 | - | - | Share Credits | |
| William C Weldon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2022 | 1,764 | 41,834 | - | - | Share Credits | |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2022 | 1,402 | 72,734 | - | - | Share Credits | |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 94.93 per share. | 17 Nov 2022 | 1,428 | 7,320 (0%) | 0% | 94.9 | 135,560 | Common Stock |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2022 | 1,323 | 25,211 | - | - | Share Credits | |
| Jeffrey R. Balser | Director | Grant, award, or other acquisition of securities at price $ 94.93 per share. | 17 Nov 2022 | 1,323 | 1,947 (0%) | 0% | 94.9 | 125,592 | Common Stock |
| Jeffrey R. Balser | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 406 | 624 (0%) | 0% | 0 | Common Stock | |
| Prem S. Shah | EVP and Co-President of Retail | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 20,376 | 20,376 | - | 0 | Common Stock (RSU) | |
| Sreekanth K Chaguturu | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 12,735 | 12,735 | - | 0 | Common Stock (RSU) | |
| Tilak Mandadi | EVP, Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 99,847 | 99,847 | - | 0 | Common Stock (RSU) | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2022 | 22,541 | 0 | - | - | Stock Option | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2022 | 50,501 | 20,201 | - | - | Stock Option | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2022 | 70,398 | 70,399 | - | - | Stock Option | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Sale of securities on an exchange or to another person at price $ 104.00 per share. | 03 Aug 2022 | 22,541 | 109,183 (0%) | 0% | 104 | 2,344,264 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.21 per share. | 03 Aug 2022 | 22,541 | 131,724 (0%) | 0% | 62.2 | 1,402,276 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Sale of securities on an exchange or to another person at price $ 98.00 per share. | 03 Aug 2022 | 50,501 | 109,183 (0%) | 0% | 98 | 4,949,098 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.19 per share. | 03 Aug 2022 | 50,501 | 159,684 (0%) | 0% | 54.2 | 2,736,649 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Sale of securities on an exchange or to another person at price $ 98.00 per share. | 03 Aug 2022 | 70,398 | 109,183 (0%) | 0% | 98 | 6,899,004 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.34 per share. | 03 Aug 2022 | 70,398 | 179,581 (0%) | 0% | 58.3 | 4,107,019 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 03 Aug 2022 | 9,546 | 32,149 (0%) | 0% | 100 | 954,600 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.37 per share. | 03 Aug 2022 | 9,546 | 41,695 (0%) | 0% | 52.4 | 499,924 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2022 | 9,546 | 19,094 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 95.00 per share. | 28 Jun 2022 | 38,873 | 626,273 (0%) | 0% | 95 | 3,692,935 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 95.00 per share. | 28 Jun 2022 | 50,502 | 626,273 (0%) | 0% | 95 | 4,797,690 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.19 per share. | 28 Jun 2022 | 50,502 | 676,775 (0%) | 0% | 54.2 | 2,736,703 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.35 per share. | 28 Jun 2022 | 49,279 | 675,552 (0%) | 0% | 58.4 | 2,875,430 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 95.00 per share. | 28 Jun 2022 | 49,279 | 626,273 (0%) | 0% | 95 | 4,681,505 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2022 | 38,873 | 116,622 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2022 | 50,502 | 50,502 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2022 | 49,279 | 98,558 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.30 per share. | 28 Jun 2022 | 38,873 | 665,146 (0%) | 0% | 74.3 | 2,888,264 | Common Stock |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 97.99 per share. | 11 May 2022 | 165 | 18,499 (0%) | 0% | 98.0 | 16,168 | Common Stock |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 1,282 | 8,222 | - | - | Share Credits | |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 97.99 per share. | 11 May 2022 | 1,282 | 27,526 (0%) | 0% | 98.0 | 125,623 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 97.99 per share. | 11 May 2022 | 1,409 | 1,409 (0%) | 0% | 98.0 | 138,068 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 1,709 | 12,142 | - | - | Share Credits | |
| Nancy-Ann Deparle M. | Director | Grant, award, or other acquisition of securities at price $ 97.99 per share. | 11 May 2022 | 1,358 | 24,760 (0%) | 0% | 98.0 | 133,070 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,112 | 17,083 | - | - | Share Credits | |
| William C Weldon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 1,760 | 39,397 | - | - | Share Credits | |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 1,358 | 70,123 | - | - | Share Credits | |
| Tony L. White | Director | Grant, award, or other acquisition of securities at price $ 98.00 per share. | 11 May 2022 | 38 | 37,852 (0%) | 0% | 98 | 3,724 | Common Stock |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 97.99 per share. | 11 May 2022 | 1,384 | 5,892 (0%) | 0% | 98.0 | 135,618 | Common Stock |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 1,282 | 23,488 | - | - | Share Credits | |
| David W. Dorman | Director | Grant, award, or other acquisition of securities at price $ 97.98 per share. | 11 May 2022 | 51 | 109,875 (0%) | 0% | 98.0 | 4,997 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 845 | 846 | - | - | Stock Option | |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 4,103 | 28,723 | - | - | Stock Option | |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 5,719 | 28,596 | - | - | Stock Option | |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 3,157 | 9,469 | - | - | Stock Option | |
| Prem S. Shah | EVP and Co-President of Retail | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 08 Apr 2022 | 3,130 | 43,453 (0%) | 0% | 105 | 328,650 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 08 Apr 2022 | 4,103 | 46,583 (0%) | 0% | 105 | 430,815 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.30 per share. | 08 Apr 2022 | 4,103 | 50,686 (0%) | 0% | 74.3 | 304,853 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 08 Apr 2022 | 5,719 | 46,583 (0%) | 0% | 105 | 600,495 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.34 per share. | 08 Apr 2022 | 5,719 | 52,302 (0%) | 0% | 58.3 | 333,646 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 08 Apr 2022 | 3,157 | 46,583 (0%) | 0% | 105 | 331,485 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.19 per share. | 08 Apr 2022 | 3,157 | 49,740 (0%) | 0% | 54.2 | 171,078 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 08 Apr 2022 | 845 | 46,583 (0%) | 0% | 105 | 88,725 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.21 per share. | 08 Apr 2022 | 845 | 47,428 (0%) | 0% | 62.2 | 52,567 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Sale of securities on an exchange or to another person at price $ 100.13 per share. | 04 Apr 2022 | 12,032 | 38,090 (0%) | 0% | 100.1 | 1,204,764 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Sale of securities on an exchange or to another person at price $ 100.13 per share. | 04 Apr 2022 | 27,166 | 50,122 (0%) | 0% | 100.1 | 2,720,132 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.34 per share. | 04 Apr 2022 | 27,166 | 77,288 (0%) | 0% | 58.3 | 1,584,864 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Sale of securities on an exchange or to another person at price $ 100.13 per share. | 04 Apr 2022 | 16,161 | 50,122 (0%) | 0% | 100.1 | 1,618,201 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.19 per share. | 04 Apr 2022 | 16,161 | 66,283 (0%) | 0% | 54.2 | 875,765 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2022 | 27,166 | 27,166 | - | - | Stock Option | |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2022 | 16,161 | 16,161 | - | - | Stock Option | |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 04 Apr 2022 | 5,941 | 32,149 (0%) | 0% | 100 | 594,100 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 25,987 | 25,987 | - | - | Stock Option | |
| Michelle A. Peluso | EVP and Co-President of Retail | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 57,172 | 57,172 | - | - | Stock Option | |
| Troyen A. Brennan | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 77,960 | 234,855 (0%) | 0% | 101.1 | 7,880,976 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 2,179 | 232,676 (0%) | 0% | 101.1 | 220,275 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 77,962 | 77,962 | - | - | Stock Option | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 38,129 | 109,183 (0%) | 0% | 101.1 | 3,854,461 | Common Stock |
| Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 171,517 | 171,517 | - | - | Stock Option | |
| Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 116,940 | 210,090 (0%) | 0% | 101.1 | 11,821,465 | Common Stock |
| Shawn M. Guertin | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 103,950 | 103,950 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 46,777 | 46,777 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 3,556 | 735,349 (0%) | 0% | 101.1 | 359,476 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 105,854 | 730,897 (0%) | 0% | 101.1 | 10,700,781 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 6,756 | 6,756 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 101.09 per share. | 01 Apr 2022 | 3,214 | 12,824 | - | 101.1 | 324,903 | Common Stock (restricted) |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 2,740 | 26,330 (0%) | 0% | 101.1 | 276,987 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 3,897 | 29,070 (0%) | 0% | 101.1 | 393,948 | Common Stock |
| Laurie P. Havanec | EVP and Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 21,829 | 21,829 | - | - | Stock Option | |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 51,975 | 51,975 | - | - | Stock Option | |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 3,856 | 50,122 (0%) | 0% | 101.1 | 389,803 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 13,532 | 44,181 (0%) | 0% | 101.1 | 1,367,950 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 41,580 | 41,580 | - | - | Stock Option | |
| Prem S. Shah | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 18,747 | 40,324 (0%) | 0% | 101.1 | 1,895,134 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 3,731 | 46,583 (0%) | 0% | 101.1 | 377,167 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 102.26 per share. | 30 Mar 2022 | 5,346 | 64,417 (0%) | 0% | 102.3 | 546,682 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Sale of securities on an exchange or to another person at price $ 104.70 per share. | 30 Mar 2022 | 5,346 | 59,071 (0%) | 0% | 104.7 | 559,726 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2022 | 5,346 | 0 | - | - | Stock Option | |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2022 | 2,935 | 2,935 | - | - | Stock Option | |
| Prem S. Shah | EVP and Co-President of Retail | Sale of securities on an exchange or to another person at price $ 106.65 per share. | 17 Mar 2022 | 2,935 | 59,071 (0%) | 0% | 106.7 | 313,018 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Exercise or conversion of derivative security received from the company (such as an option) at price $ 104.82 per share. | 17 Mar 2022 | 2,935 | 62,006 (0%) | 0% | 104.8 | 307,647 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Sale of securities on an exchange or to another person at price $ 106.65 per share. | 17 Mar 2022 | 1,689 | 59,071 (0%) | 0% | 106.7 | 180,132 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 51,361 | 0 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 102.26 per share. | 15 Mar 2022 | 51,361 | 888,112 (0%) | 0% | 102.3 | 5,252,176 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 15 Mar 2022 | 51,361 | 836,751 (0%) | 0% | 105 | 5,392,905 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.65 per share. | 28 Feb 2022 | 183 | 26,334 (0%) | 0% | 103.7 | 18,968 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.65 per share. | 28 Feb 2022 | 253 | 26,668 (0%) | 0% | 103.6 | 26,223 | Common Stock |
| Michelle A. Peluso | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 104.30 per share. | 26 Feb 2022 | 12,609 | 14,911 (0%) | 0% | 104.3 | 1,315,119 | Common Stock |
| Laurie P. Havanec | EVP and Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 104.30 per share. | 26 Feb 2022 | 5,233 | 9,754 (0%) | 0% | 104.3 | 545,802 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.65 per share. | 26 Feb 2022 | 141 | 60,760 (0%) | 0% | 103.7 | 14,615 | Common Stock |
| Prem S. Shah | EVP and Co-President of Retail | Payment of exercise price or tax liability using portion of securities received from the company at price $ 104.30 per share. | 26 Feb 2022 | 226 | 59,394 (0%) | 0% | 104.3 | 23,572 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 322,395 | 426,024 (0%) | 0% | 0 | Common Stock | |
| Troyen A. Brennan | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 171,944 | 312,815 (0%) | 0% | 0 | Common Stock | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 85,971 | 147,312 (0%) | 0% | 0 | Common Stock | |
| Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 257,916 | 327,030 (0%) | 0% | 0 | Common Stock | |
| Thomas M. Moriarty | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 214,930 | 836,751 (0%) | 0% | 0 | Common Stock | |
| Thomas M. Moriarty | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 572,542 | 621,821 (0%) | 0% | 0 | Common Stock | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 8,595 | 26,092 (0%) | 0% | 0 | Common Stock | |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 34,387 | 57,713 (0%) | 0% | 0 | Common Stock | |
| Prem S. Shah | EVP and Co-President of Retail | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 47,640 | 59,620 (0%) | 0% | 0 | Common Stock | |
| Edward J. Ludwig | Director | Purchase of securities on an exchange or from another person at price $ 105.90 per share. | 10 Feb 2022 | 1,000 | 18,334 (0%) | 0% | 105.9 | 105,904 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2022 | 47,937 | 0 | - | - | Stock Option | |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 102.26 per share. | 03 Feb 2022 | 47,937 | 186,183 (0%) | 0% | 102.3 | 4,902,038 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 03 Feb 2022 | 47,937 | 138,246 (0%) | 0% | 110 | 5,273,070 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Sale of securities on an exchange or to another person at price $ 106.50 per share. | 01 Feb 2022 | 21,386 | 61,341 (0%) | 0% | 106.5 | 2,277,566 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 21,386 | 0 | - | - | Stock Option | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Exercise or conversion of derivative security received from the company (such as an option) at price $ 102.26 per share. | 01 Feb 2022 | 21,386 | 82,727 (0%) | 0% | 102.3 | 2,186,932 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2022 | 6,059 | 0 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Sale of securities on an exchange or to another person at price $ 109.00 per share. | 28 Jan 2022 | 6,059 | 17,497 (0%) | 0% | 109 | 660,431 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 102.26 per share. | 28 Jan 2022 | 6,059 | 23,556 (0%) | 0% | 102.3 | 619,593 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 102.26 per share. | 27 Jan 2022 | 68,482 | 175,596 (0%) | 0% | 102.3 | 7,002,969 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 107.50 per share. | 27 Jan 2022 | 68,482 | 107,114 (0%) | 0% | 107.5 | 7,361,815 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2022 | 68,482 | 0 | - | - | Stock Option | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.78 per share. | 27 Dec 2021 | 200 | 5,827 (0%) | 0% | 88.8 | 17,756 | Common Stock (restricted) |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.78 per share. | 01 Dec 2021 | 266 | 16,723 | - | 88.8 | 23,615 | Common Stock (restricted) |
| Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.52 per share. | 28 Nov 2021 | 14,121 | 69,114 (0%) | 0% | 91.5 | 1,292,354 | Common Stock |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 1,354 | 6,905 | - | - | Share Credits | |
| David W. Dorman | Director | Grant, award, or other acquisition of securities at price $ 92.73 per share. | 17 Nov 2021 | 3,154 | 109,824 (0%) | 0% | 92.7 | 292,470 | Common Stock |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 92.73 per share. | 17 Nov 2021 | 1,253 | 26,244 (0%) | 0% | 92.7 | 116,191 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 92.73 per share. | 17 Nov 2021 | 1,253 | 1,253 (0%) | 0% | 92.7 | 116,191 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 92.73 per share. | 17 Nov 2021 | 417 | 7,585 (0%) | 0% | 92.7 | 38,668 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 1,253 | 14,638 | - | - | Share Credits | |
| Nancy-Ann Deparle | Director | Grant, award, or other acquisition of securities at price $ 92.73 per share. | 17 Nov 2021 | 1,334 | 23,402 (0%) | 0% | 92.7 | 123,702 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 1,671 | 13,899 | - | - | Share Credits | |
| William C Weldon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 1,671 | 37,361 | - | - | Share Credits | |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 1,779 | 68,107 | - | - | Share Credits | |
| Tony L. White | Director | Grant, award, or other acquisition of securities at price $ 92.73 per share. | 17 Nov 2021 | 1,314 | 37,814 (0%) | 0% | 92.7 | 121,847 | Common Stock |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 92.73 per share. | 17 Nov 2021 | 1,314 | 1,314 (0%) | 0% | 92.7 | 121,847 | Common Stock |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 1,253 | 22,051 | - | - | Share Credits | |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 95.00 per share. | 03 Nov 2021 | 108,870 | 107,114 (0%) | 0% | 95 | 10,342,650 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2021 | 108,870 | 0 | - | - | Stock Option | |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.93 per share. | 03 Nov 2021 | 108,870 | 215,984 (0%) | 0% | 45.9 | 5,000,399 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 28,159 | 84,478 | - | - | Stock Option | |
| Troyen A. Brennan | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 01 Nov 2021 | 28,159 | 138,246 (0%) | 0% | 90 | 2,534,310 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.34 per share. | 01 Nov 2021 | 28,159 | 166,405 (0%) | 0% | 58.3 | 1,642,796 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.19 per share. | 26 Oct 2021 | 80,802 | 221,003 (0%) | 0% | 54.2 | 4,378,660 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2021 | 80,802 | 80,803 | - | - | Stock Option | |
| Troyen A. Brennan | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 88.00 per share. | 26 Oct 2021 | 80,802 | 138,246 (0%) | 0% | 88 | 7,110,576 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 88.00 per share. | 26 Oct 2021 | 1,955 | 219,048 (0%) | 0% | 88 | 172,040 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 87.00 per share. | 02 Sep 2021 | 2,625 | 140,201 (0%) | 0% | 87 | 228,375 | Common Stock |
| Edward J. Ludwig | Director | Purchase of securities on an exchange or from another person at price $ 79.54 per share. | 05 Aug 2021 | 3,000 | 17,334 (0%) | 0% | 79.5 | 238,635 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Sale of securities on an exchange or to another person at price $ 83.67 per share. | 28 Jun 2021 | 2,781 | 61,047 (0%) | 0% | 83.7 | 232,686 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.21 per share. | 15 Jun 2021 | 65,681 | 210,378 (0%) | 0% | 62.2 | 4,086,015 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 65,681 | 21,894 | - | - | Stock Option | |
| Troyen A. Brennan | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 86.00 per share. | 15 Jun 2021 | 67,552 | 142,826 (0%) | 0% | 86 | 5,809,472 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.19 per share. | 07 Jun 2021 | 32,320 | 60,903 (0%) | 0% | 54.2 | 1,751,421 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 32,320 | 32,322 | - | - | Stock Option | |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Sale of securities on an exchange or to another person at price $ 86.60 per share. | 07 Jun 2021 | 37,594 | 23,309 (0%) | 0% | 86.6 | 3,255,640 | Common Stock |
| Larry J. Merlo | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.44 per share. | 31 May 2021 | 634 | 632,312 (0%) | 0% | 86.4 | 54,803 | Common Stock |
| Shawn M. Guertin | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 97,562 | 97,562 | - | - | Stock Option | |
| Shawn M. Guertin | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 86.44 per share. | 28 May 2021 | 34,706 | 34,706 (0%) | 0% | 86.4 | 2,999,987 | Common Stock (restricted) |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 1,490 | 5,586 | - | - | Share Credits | |
| David W. Dorman | Director | Grant, award, or other acquisition of securities at price $ 84.27 per share. | 13 May 2021 | 3,470 | 106,670 (0%) | 0% | 84.3 | 292,417 | Common Stock |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 84.27 per share. | 13 May 2021 | 1,379 | 24,991 (0%) | 0% | 84.3 | 116,208 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 84.27 per share. | 13 May 2021 | 1,379 | 1,379 (0%) | 0% | 84.3 | 116,208 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 1,379 | 13,230 | - | - | Share Credits | |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 84.27 per share. | 13 May 2021 | 459 | 7,168 (0%) | 0% | 84.3 | 38,680 | Common Stock |
| Nancy-Ann Deparle | Director | Grant, award, or other acquisition of securities at price $ 84.27 per share. | 13 May 2021 | 1,468 | 22,068 (0%) | 0% | 84.3 | 123,708 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 1,839 | 12,087 | - | - | Share Credits | |
| William C Weldon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 1,839 | 35,360 | - | - | Share Credits | |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 1,957 | 65,866 | - | - | Share Credits | |
| Tony L. White | Director | Grant, award, or other acquisition of securities at price $ 84.27 per share. | 13 May 2021 | 1,446 | 36,500 (0%) | 0% | 84.3 | 121,854 | Common Stock |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 84.27 per share. | 13 May 2021 | 1,446 | 1,446 (0%) | 0% | 84.3 | 121,854 | Common Stock |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 1,379 | 20,599 | - | - | Share Credits | |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 109,469 | 36,490 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 86.00 per share. | 10 May 2021 | 109,469 | 0 (0%) | 0% | 86 | 9,414,334 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.21 per share. | 10 May 2021 | 109,469 | 109,469 (0%) | 0% | 62.2 | 6,810,066 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 84.00 per share. | 07 May 2021 | 9,477 | 144,697 (0%) | 0% | 84 | 796,068 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.34 per share. | 04 May 2021 | 49,279 | 49,279 (0%) | 0% | 58.3 | 2,874,937 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2021 | 49,279 | 147,837 | - | - | Stock Option | |
| Eva C. Boratto | EVP & CFO | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 04 May 2021 | 4,905 | 115,331 (0%) | 0% | 80 | 392,400 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.19 per share. | 21 Apr 2021 | 101,003 | 103,423 (0%) | 0% | 54.2 | 5,473,353 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2021 | 101,003 | 101,004 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 77.00 per share. | 21 Apr 2021 | 2,420 | 0 (0%) | 0% | 77 | 186,340 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 77.00 per share. | 21 Apr 2021 | 101,003 | 2,420 (0%) | 0% | 77 | 7,777,231 | Common Stock |
| Alan M. Lotvin | EVP&President-PharmacyServices | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 03 Apr 2021 | 1,705 | 63,828 (0%) | 0% | 74.3 | 126,682 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 03 Apr 2021 | 480 | 17,497 (0%) | 0% | 74.3 | 35,664 | Common Stock |
| Neela Montgomery | EVP and Pres., Pharmacy/Retail | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 86,386 | 86,386 | - | - | Stock Option | |
| Laurie P. Havanec | EVP and Chief People Officer | 01 Apr 2021 | 27,643 | 27,643 | - | - | Stock Option | ||
| James D. Clark | SVP, Cont & Chief Acct Officer | Sale of securities on an exchange or to another person at price $ 76.00 per share. | 31 Mar 2021 | 5,350 | 7,244 (0%) | 0% | 76 | 406,600 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2021 | 5,350 | 0 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.29 per share. | 31 Mar 2021 | 5,350 | 12,594 (0%) | 0% | 74.3 | 397,452 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.29 per share. | 29 Mar 2021 | 62,943 | 62,943 (0%) | 0% | 74.3 | 4,676,035 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 76.15 per share. | 29 Mar 2021 | 62,943 | 0 (0%) | 0% | 76.1 | 4,793,109 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2021 | 62,943 | 0 | - | - | Stock Option | |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2021 | 73,433 | 0 | - | - | Stock Option | |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 74.49 per share. | 26 Mar 2021 | 73,433 | 663 (0%) | 0% | 74.5 | 5,470,024 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.29 per share. | 26 Mar 2021 | 73,433 | 74,096 (0%) | 0% | 74.3 | 5,455,338 | Common Stock |
| Larry J. Merlo | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2021 | 271,347 | 0 | - | - | Stock Option | |
| Larry J. Merlo | Director | Sale of securities on an exchange or to another person at price $ 74.73 per share. | 26 Mar 2021 | 270,650 | 524,025 (0%) | 0% | 74.7 | 20,225,675 | Common Stock |
| Larry J. Merlo | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.29 per share. | 26 Mar 2021 | 271,347 | 794,675 (0%) | 0% | 74.3 | 20,158,369 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 74.15 per share. | 19 Mar 2021 | 49,211 | 18,226 (0%) | 0% | 74.2 | 3,648,996 | Common Stock |
| Eva C. Boratto | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2021 | 18,882 | 0 | - | - | Stock Option | |
| Eva C. Boratto | EVP & CFO | Sale of securities on an exchange or to another person at price $ 74.68 per share. | 16 Mar 2021 | 18,882 | 71,082 (0%) | 0% | 74.7 | 1,410,108 | Common Stock |
| Eva C. Boratto | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.29 per share. | 16 Mar 2021 | 18,882 | 89,964 (0%) | 0% | 74.3 | 1,402,744 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.94 per share. | 02 Mar 2021 | 2,413 | 15,073 (0%) | 0% | 68.9 | 166,352 | Common Stock |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 28 Feb 2021 | 572 | 25,656 (0%) | 0% | 0 | Common Stock | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.13 per share. | 28 Feb 2021 | 1,129 | 7,244 (0%) | 0% | 68.1 | 76,919 | Common Stock |
| Laurie P. Havanec | EVP and Chief People Officer | 26 Feb 2021 | 44,033 | 44,033 | - | 68.1 | 2,999,968 | Common Stock (restricted) | |
| Edward J. Ludwig | Director | Purchase of securities on an exchange or from another person at price $ 72.00 per share. | 17 Feb 2021 | 3,000 | 14,334 (0%) | 0% | 72 | 216,000 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 175,811 | 176,474 (0%) | 0% | 0 | Common Stock | |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 79,714 | 96,760 (0%) | 0% | 74.3 | 5,922,750 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 172,772 | 172,772 | - | - | Stock Option | |
| Larry J. Merlo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 180,192 | 703,520 (0%) | 0% | 0 | Common Stock | |
| Larry J. Merlo | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 81,700 | 622,517 (0%) | 0% | 74.3 | 6,070,310 | Common Stock |
| Larry J. Merlo | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Feb 2021 | 8,651 | 632,946 (0%) | 0% | 0 | Common Stock | |
| Troyen A. Brennan | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 99,344 | 99,344 | - | - | Stock Option | |
| Troyen A. Brennan | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 1,623 | 154,174 (0%) | 0% | 74.3 | 120,589 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 42,855 | 152,219 (0%) | 0% | 74.3 | 3,184,127 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 94,516 | 195,074 (0%) | 0% | 0 | Common Stock | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 120,940 | 120,940 | - | - | Stock Option | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Feb 2021 | 42,431 | 61,690 (0%) | 0% | 0 | Common Stock | |
| Alan M. Lotvin | EVP&President-PharmacyServices | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 95,669 | 104,121 (0%) | 0% | 0 | Common Stock | |
| Karen S. Lynch | EVP and President, Aetna | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 224,604 | 224,604 | - | - | Stock Option | |
| Karen S. Lynch | EVP and President, Aetna | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 43,211 | 52,091 (0%) | 0% | 74.3 | 3,210,577 | Common Stock |
| Karen S. Lynch | EVP and President, Aetna | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 95,302 | 95,302 (0%) | 0% | 0 | Common Stock | |
| Thomas M. Moriarty | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 2,350 | 65,373 (0%) | 0% | 74.3 | 174,605 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 155,495 | 155,495 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 61,095 | 62,953 (0%) | 0% | 74.3 | 4,539,359 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 124,048 | 124,048 (0%) | 0% | 0 | Common Stock | |
| Lisa Bisaccia | Former EVP & Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 77,457 | 100,103 (0%) | 0% | 0 | Common Stock | |
| Lisa Bisaccia | Former EVP & Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 35,120 | 64,983 (0%) | 0% | 74.3 | 2,609,416 | Common Stock |
| Lisa Bisaccia | Former EVP & Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 1,190 | 66,417 (0%) | 0% | 74.3 | 88,417 | Common Stock |
| Eva C. Boratto | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 88,500 | 159,582 (0%) | 0% | 0 | Common Stock | |
| Eva C. Boratto | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 40,128 | 119,454 (0%) | 0% | 74.3 | 2,981,510 | Common Stock |
| Eva C. Boratto | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 649 | 120,236 (0%) | 0% | 74.3 | 48,221 | Common Stock |
| Eva C. Boratto | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 103,663 | 103,663 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 13,113 | 17,930 (0%) | 0% | 0 | Common Stock | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 5,246 | 15,111 (0%) | 0% | 74.3 | 389,778 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 1,503 | 16,920 (0%) | 0% | 74.3 | 111,673 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 74.30 per share. | 01 Feb 2021 | 4,710 | 18,046 (0%) | 0% | 74.3 | 349,953 | Common Stock (restricted) |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 12,094 | 12,094 | - | - | Stock Option | |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 4,540 | 28,565 (0%) | 0% | 74.3 | 337,322 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 14,280 | 24,079 (0%) | 0% | 0 | Common Stock | |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 6,044 | 23,309 (0%) | 0% | 74.3 | 449,069 | Common Stock |
| Daniel P. Finke | EVP/Pres, Health Care Benefits | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 82,066 | 82,066 | - | - | Stock Option | |
| Larry J. Merlo | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.29 per share. | 19 Jan 2021 | 64,350 | 586,221 (0%) | 0% | 74.3 | 4,780,562 | Common Stock |
| Larry J. Merlo | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 64,350 | 271,347 | - | - | Stock Option | |
| Larry J. Merlo | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 77.00 per share. | 19 Jan 2021 | 62,893 | 523,328 (0%) | 0% | 77 | 4,842,761 | Common Stock |
| Lisa Bisaccia | EVP and Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2021 | 25,177 | 0 | - | - | Stock Option | |
| Lisa Bisaccia | EVP and Chief HR Officer | Sale of securities on an exchange or to another person at price $ 77.00 per share. | 12 Jan 2021 | 25,177 | 46,588 (0%) | 0% | 77 | 1,938,629 | Common Stock |
| Lisa Bisaccia | EVP and Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.29 per share. | 12 Jan 2021 | 25,177 | 71,765 (0%) | 0% | 74.3 | 1,870,399 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 08 Jan 2021 | 58,896 | 46,008 (0%) | 0% | 75 | 4,417,200 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.29 per share. | 08 Jan 2021 | 54,550 | 100,558 (0%) | 0% | 74.3 | 4,052,520 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 54,550 | 0 | - | - | Stock Option | |
| Alan M. Lotvin | EVP and President-CVS Caremark | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.19 per share. | 08 Jan 2021 | 10,100 | 18,468 (0%) | 0% | 54.2 | 547,319 | Common Stock |
| Alan M. Lotvin | EVP and President-CVS Caremark | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 08 Jan 2021 | 25,836 | 8,368 (0%) | 0% | 75 | 1,937,700 | Common Stock |
| Alan M. Lotvin | EVP and President-CVS Caremark | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.29 per share. | 08 Jan 2021 | 15,736 | 34,204 (0%) | 0% | 74.3 | 1,169,027 | Common Stock |
| Alan M. Lotvin | EVP and President-CVS Caremark | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 15,736 | 0 | - | - | Stock Option | |
| Alan M. Lotvin | EVP and President-CVS Caremark | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 10,100 | 70,702 | - | - | Stock Option | |
| Karen S. Lynch | EVP and President, Aetna | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.63 per share. | 02 Dec 2020 | 12,779 | 94,370 (0%) | 0% | 69.6 | 889,802 | Common Stock |
| Jonathan E. Mayhew | EVP - Transformation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.63 per share. | 02 Dec 2020 | 926 | 6,855 (0%) | 0% | 69.6 | 64,477 | Common Stock |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2020 | 1,893 | 3,942 | - | - | Share Credits | |
| David W. Dorman | Director | Grant, award, or other acquisition of securities at price $ 66.35 per share. | 18 Nov 2020 | 4,408 | 140,900 (0%) | 0% | 66.4 | 292,471 | Common Stock |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 66.35 per share. | 18 Nov 2020 | 1,752 | 23,612 (0%) | 0% | 66.3 | 116,245 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 66.35 per share. | 18 Nov 2020 | 1,752 | 1,752 (0%) | 0% | 66.3 | 116,245 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 66.35 per share. | 18 Nov 2020 | 2,336 | 6,709 (0%) | 0% | 66.4 | 154,994 | Common Stock |
| Nancy-Ann Deparle | Director | Grant, award, or other acquisition of securities at price $ 66.35 per share. | 18 Nov 2020 | 1,836 | 20,600 (0%) | 0% | 66.4 | 121,819 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2020 | 2,336 | 10,111 | - | - | Share Credits | |
| William C Weldon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2020 | 2,336 | 33,075 | - | - | Share Credits | |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 66.35 per share. | 18 Nov 2020 | 1,865 | 119,120 (0%) | 0% | 66.4 | 123,743 | Common Stock |
| Tony L. White | Director | Grant, award, or other acquisition of securities at price $ 66.35 per share. | 18 Nov 2020 | 1,836 | 35,054 (0%) | 0% | 66.4 | 121,819 | Common Stock |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2020 | 1,836 | 9,959 | - | - | Share Credits | |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2020 | 1,752 | 18,964 | - | - | Share Credits | |
| Alan Lotvin | EVP and President-CVS Caremark | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 13 Nov 2020 | 7,138 | 8,023 (0%) | 0% | 70 | 499,660 | Common Stock |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2020 | 21,460 | 0 | - | - | Stock Option | |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.96 per share. | 10 Nov 2020 | 21,460 | 46,460 (0%) | 0% | 35.0 | 750,242 | Common Stock |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 10 Nov 2020 | 21,460 | 25,000 (0%) | 0% | 70 | 1,502,200 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 26 May 2020 | 270 | 4,547 (0%) | 0% | 65 | 17,550 | Common Stock |
| Jonathan E. Mayhew | EVP - Transformation | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 26 May 2020 | 10,556 | 4,732 (0%) | 0% | 65 | 686,140 | Common Stock |
| Edward J. Ludwig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2020 | 2,016 | 2,016 | - | - | Share Credits | |
| David W. Dorman | Director | Grant, award, or other acquisition of securities at price $ 62.31 per share. | 14 May 2020 | 4,694 | 136,492 (0%) | 0% | 62.3 | 292,483 | Common Stock |
| Fernando Aguirre | Director | Grant, award, or other acquisition of securities at price $ 62.31 per share. | 14 May 2020 | 1,865 | 21,860 (0%) | 0% | 62.3 | 116,208 | Common Stock |
| Jean-Pierre Millon | Director | Grant, award, or other acquisition of securities at price $ 62.31 per share. | 14 May 2020 | 1,865 | 1,865 (0%) | 0% | 62.3 | 116,208 | Common Stock |
| Mary L. Schapiro | Director | Grant, award, or other acquisition of securities at price $ 62.31 per share. | 14 May 2020 | 2,487 | 4,373 (0%) | 0% | 62.3 | 154,965 | Common Stock |
| Nancy-Ann Deparle | Director | Grant, award, or other acquisition of securities at price $ 62.31 per share. | 14 May 2020 | 1,955 | 18,764 (0%) | 0% | 62.3 | 121,816 | Common Stock |
| Roger N. Farah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2020 | 2,487 | 7,649 | - | - | Share Credits | |
| William C Weldon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2020 | 2,487 | 30,240 | - | - | Share Credits | |
| C. David Brown | Director | Grant, award, or other acquisition of securities at price $ 62.31 per share. | 14 May 2020 | 1,986 | 117,255 (0%) | 0% | 62.3 | 123,748 | Common Stock |
| Tony L. White | Director | Grant, award, or other acquisition of securities at price $ 62.31 per share. | 14 May 2020 | 1,955 | 33,218 (0%) | 0% | 62.3 | 121,816 | Common Stock |
| Anne M. Finucane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2020 | 1,955 | 7,991 | - | - | Share Credits | |
| Alecia A. DeCoudreaux | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2020 | 1,865 | 16,932 | - | - | Share Credits | |
| Alan Lotvin | EVP and President-CVS Caremark | Purchase of securities on an exchange or from another person at price $ 63.14 per share. | 11 May 2020 | 5,000 | 15,161 (0%) | 0% | 63.1 | 315,675 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 28 Apr 2020 | 6,234 | 4,817 (0%) | 0% | 65 | 405,210 | Common Stock |
| Larry J. Merlo | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.72 per share. | 03 Apr 2020 | 9,803 | 521,871 (0%) | 0% | 55.7 | 546,223 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.72 per share. | 03 Apr 2020 | 2,179 | 104,904 (0%) | 0% | 55.7 | 121,414 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.72 per share. | 03 Apr 2020 | 3,944 | 67,437 (0%) | 0% | 55.7 | 219,760 | Common Stock |
| Lisa Bisaccia | EVP and Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.72 per share. | 03 Apr 2020 | 1,598 | 46,588 (0%) | 0% | 55.7 | 89,041 | Common Stock |
| Eva C. Boratto | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.72 per share. | 03 Apr 2020 | 1,017 | 70,745 (0%) | 0% | 55.7 | 56,667 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 239,355 | 239,355 | - | - | Stock Option | |
| Larry J. Merlo | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 478,711 | 478,711 | - | - | Stock Option | |
| Troyen A. Brennan | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 112,637 | 112,637 | - | - | Stock Option | |
| Alan Lotvin | EVP, Transformation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 140,797 | 140,797 | - | - | Stock Option | |
| Karen S. Lynch | EVP & Pres, Aetna Bus Unit | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 211,196 | 211,196 | - | - | Stock Option | |
| Thomas M. Moriarty | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 197,116 | 197,116 | - | - | Stock Option | |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 63,358 | 63,358 | - | - | Stock Option | |
| Lisa Bisaccia | EVP and Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 98,558 | 98,558 | - | - | Stock Option | |
| Eva C. Boratto | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 168,956 | 168,956 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 58.34 per share. | 01 Apr 2020 | 7,713 | 20,204 | - | 58.3 | 449,976 | Common Stock (restricted) |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.34 per share. | 01 Apr 2020 | 681 | 11,321 (0%) | 0% | 58.3 | 39,730 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 17,157 | 17,157 | - | - | Stock Option | |
| Jonathan E. Mayhew | EVP, Chief Transformation Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 28,159 | 28,159 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.53 per share. | 30 Mar 2020 | 3,030 | 12,790 (0%) | 0% | 54.5 | 165,226 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2020 | 3,030 | 0 | - | - | Stock Option | |
| James D. Clark | SVP, Cont & Chief Acct Officer | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 30 Mar 2020 | 3,030 | 9,760 (0%) | 0% | 60 | 181,800 | Common Stock |
| Derica W. Rice | EVP & President, CVS Caremark | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 8,079 | 26,827 (0%) | 0% | 59.2 | 478,115 | Common Stock |
| Derica W. Rice | EVP & President, CVS Caremark | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 21,943 | 34,906 (0%) | 0% | 59.2 | 1,298,587 | Common Stock |
| Jonathan C. Roberts | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 63,366 | 295,406 (0%) | 0% | 59.2 | 3,750,000 | Stock Unit |
| Larry J. Merlo | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 114,058 | 551,078 (0%) | 0% | 59.2 | 6,749,952 | Common Stock |
| Larry J. Merlo | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 51,714 | 499,364 (0%) | 0% | 59.2 | 3,060,435 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 25,346 | 109,663 (0%) | 0% | 59.2 | 1,499,976 | Common Stock |
| Troyen A. Brennan | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 9,255 | 100,408 (0%) | 0% | 59.2 | 547,711 | Common Stock |
| Alan Lotvin | EVP, Transformation | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 11,828 | 27,945 (0%) | 0% | 59.2 | 699,981 | Stock Unit |
| Alan Lotvin | EVP, Transformation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 160 | 8,303 (0%) | 0% | 59.2 | 9,469 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 31,683 | 74,970 (0%) | 0% | 59.2 | 1,875,000 | Common Stock |
| Thomas M. Moriarty | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 13,457 | 61,513 (0%) | 0% | 59.2 | 796,385 | Common Stock |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 1,026 | 23,827 (0%) | 0% | 59.2 | 60,719 | Common Stock |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 498 | 21,474 (0%) | 0% | 59.2 | 29,472 | Common Stock |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 3,379 | 24,853 (0%) | 0% | 59.2 | 199,969 | Common Stock |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Grant, award, or other acquisition of securities at price $ 59.00 per share. | 28 Feb 2020 | 1 | 13,691 (0%) | 0% | 59 | 59 | Common Stock (restricted) |
| Lisa Bisaccia | EVP and Chief HR Officer | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 18,587 | 49,529 (0%) | 0% | 59.2 | 1,099,979 | Common Stock |
| Lisa Bisaccia | EVP and Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 6,202 | 43,327 (0%) | 0% | 59.2 | 367,034 | Common Stock |
| Eva C. Boratto | EVP & CFO | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 33,795 | 81,644 (0%) | 0% | 59.2 | 1,999,988 | Common Stock |
| Eva C. Boratto | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 137 | 47,849 (0%) | 0% | 59.2 | 8,108 | Common Stock |
| Eva C. Boratto | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 13,193 | 68,451 (0%) | 0% | 59.2 | 780,762 | Common Stock |
| James D. Clark | SVP, Cont & Chief Acct Officer | Grant, award, or other acquisition of securities at price $ 59.18 per share. | 28 Feb 2020 | 1,912 | 14,733 (0%) | 0% | 59.2 | 113,152 | Common Stock (restricted) |
| James D. Clark | SVP, Cont & Chief Acct Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.18 per share. | 28 Feb 2020 | 347 | 9,760 (0%) | 0% | 59.2 | 20,535 | Common Stock |
| Joshua Flum | EVP, ENT STRATEGY & DIGITAL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.33 per share. | 27 Feb 2020 | 844 | 20,338 (0%) | 0% | 59.3 | 50,075 | Common Stock |
| Karen S. Lynch | EVP & Pres, Aetna Bus Unit | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 18 Feb 2020 | 14,215 | 78,966 (0%) | 0% | 0 | Common Stock |